| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cloud Computing | 5 | 2024 | 11 | 2.900 |
Why?
|
| Genomics | 12 | 2021 | 720 | 2.440 |
Why?
|
| Software | 10 | 2023 | 654 | 2.270 |
Why?
|
| Neoplasms | 16 | 2023 | 2898 | 1.730 |
Why?
|
| Biomedical Research | 6 | 2022 | 376 | 1.670 |
Why?
|
| Genome, Human | 8 | 2021 | 756 | 1.650 |
Why?
|
| Information Dissemination | 6 | 2021 | 103 | 1.620 |
Why?
|
| Electronic Health Records | 3 | 2024 | 320 | 1.550 |
Why?
|
| Databases, Factual | 6 | 2020 | 816 | 1.120 |
Why?
|
| Datasets as Topic | 3 | 2017 | 71 | 1.080 |
Why?
|
| Veterans | 2 | 2024 | 72 | 1.070 |
Why?
|
| Databases, Genetic | 3 | 2021 | 260 | 1.020 |
Why?
|
| Vocabulary, Controlled | 1 | 2023 | 13 | 0.910 |
Why?
|
| Genome, Bacterial | 3 | 2022 | 139 | 0.910 |
Why?
|
| Computational Biology | 6 | 2019 | 528 | 0.900 |
Why?
|
| Data Accuracy | 2 | 2022 | 31 | 0.880 |
Why?
|
| Medical Informatics | 2 | 2024 | 47 | 0.870 |
Why?
|
| Whole Genome Sequencing | 2 | 2022 | 76 | 0.850 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2022 | 12 | 0.840 |
Why?
|
| Antitubercular Agents | 1 | 2022 | 52 | 0.830 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2022 | 44 | 0.820 |
Why?
|
| Medical Oncology | 4 | 2024 | 359 | 0.810 |
Why?
|
| Precision Medicine | 9 | 2024 | 395 | 0.800 |
Why?
|
| Drosophila melanogaster | 6 | 2014 | 599 | 0.740 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2022 | 186 | 0.700 |
Why?
|
| Disease | 2 | 2017 | 90 | 0.690 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 526 | 0.690 |
Why?
|
| Mutation | 6 | 2024 | 3968 | 0.660 |
Why?
|
| Gene Regulatory Networks | 3 | 2010 | 296 | 0.660 |
Why?
|
| Spatial Analysis | 1 | 2017 | 7 | 0.620 |
Why?
|
| Information Storage and Retrieval | 4 | 2023 | 120 | 0.610 |
Why?
|
| Data Collection | 1 | 2018 | 372 | 0.590 |
Why?
|
| Neuroblastoma | 2 | 2019 | 375 | 0.590 |
Why?
|
| Algorithms | 5 | 2018 | 1830 | 0.570 |
Why?
|
| Genome-Wide Association Study | 4 | 2020 | 1621 | 0.560 |
Why?
|
| Humans | 50 | 2024 | 86678 | 0.550 |
Why?
|
| Computer Systems | 1 | 2014 | 79 | 0.470 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 813 | 0.470 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 827 | 0.460 |
Why?
|
| United States | 12 | 2023 | 6681 | 0.440 |
Why?
|
| Data Mining | 2 | 2014 | 42 | 0.440 |
Why?
|
| Liquid Biopsy | 3 | 2023 | 33 | 0.430 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 1921 | 0.430 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 1721 | 0.430 |
Why?
|
| DNA Methylation | 4 | 2021 | 628 | 0.430 |
Why?
|
| National Cancer Institute (U.S.) | 4 | 2021 | 70 | 0.420 |
Why?
|
| Systems Biology | 1 | 2012 | 42 | 0.410 |
Why?
|
| Databases, Nucleic Acid | 1 | 2011 | 41 | 0.390 |
Why?
|
| Molecular Sequence Annotation | 3 | 2021 | 67 | 0.380 |
Why?
|
| Transcription Factors | 7 | 2014 | 1565 | 0.380 |
Why?
|
| Phenotype | 5 | 2022 | 2380 | 0.380 |
Why?
|
| Models, Statistical | 2 | 2018 | 575 | 0.350 |
Why?
|
| User-Computer Interface | 3 | 2021 | 185 | 0.340 |
Why?
|
| Models, Molecular | 2 | 2004 | 1286 | 0.340 |
Why?
|
| Base Sequence | 5 | 2021 | 2330 | 0.330 |
Why?
|
| Reproducibility of Results | 6 | 2023 | 2706 | 0.310 |
Why?
|
| Genome, Insect | 3 | 2014 | 75 | 0.310 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1464 | 0.300 |
Why?
|
| Computer Security | 3 | 2019 | 16 | 0.290 |
Why?
|
| Sequence Analysis, DNA | 3 | 2018 | 853 | 0.290 |
Why?
|
| Computer Graphics | 1 | 2006 | 100 | 0.280 |
Why?
|
| Multiple Sclerosis | 4 | 2002 | 262 | 0.280 |
Why?
|
| Genome | 1 | 2009 | 372 | 0.280 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 297 | 0.250 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 2271 | 0.250 |
Why?
|
| Computer Communication Networks | 2 | 2016 | 23 | 0.250 |
Why?
|
| Chemistry | 1 | 2004 | 54 | 0.240 |
Why?
|
| Organic Chemicals | 1 | 2004 | 33 | 0.240 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 1001 | 0.240 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 3 | 2014 | 148 | 0.230 |
Why?
|
| Halomonadaceae | 2 | 2013 | 4 | 0.230 |
Why?
|
| Chromatin | 5 | 2014 | 381 | 0.220 |
Why?
|
| Internet | 3 | 2017 | 312 | 0.220 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 37 | 0.220 |
Why?
|
| Terminology as Topic | 1 | 2004 | 217 | 0.210 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 122 | 0.210 |
Why?
|
| Models, Biological | 1 | 2009 | 1749 | 0.210 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2011 | 133 | 0.210 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 143 | 0.200 |
Why?
|
| Pharmaceutical Preparations | 1 | 2003 | 92 | 0.200 |
Why?
|
| 5-Methylcytosine | 2 | 2019 | 112 | 0.190 |
Why?
|
| Specimen Handling | 1 | 2021 | 98 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2002 | 3362 | 0.190 |
Why?
|
| Viruses | 1 | 2021 | 78 | 0.190 |
Why?
|
| Chromothripsis | 1 | 2020 | 5 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2022 | 170 | 0.180 |
Why?
|
| Academic Success | 1 | 2020 | 11 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 3 | 2020 | 937 | 0.180 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 171 | 0.180 |
Why?
|
| Oncogenes | 1 | 2020 | 88 | 0.180 |
Why?
|
| Veterans Health | 1 | 2019 | 15 | 0.180 |
Why?
|
| Telomerase | 1 | 2020 | 55 | 0.180 |
Why?
|
| Mutagenesis | 1 | 2020 | 199 | 0.180 |
Why?
|
| Cellular Senescence | 1 | 2020 | 94 | 0.170 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 329 | 0.170 |
Why?
|
| Ecosystem | 2 | 2023 | 316 | 0.170 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 2262 | 0.170 |
Why?
|
| Telomere | 1 | 2020 | 108 | 0.170 |
Why?
|
| Epigenomics | 1 | 2019 | 100 | 0.170 |
Why?
|
| Prognosis | 3 | 2022 | 3680 | 0.170 |
Why?
|
| Schools, Medical | 1 | 2020 | 123 | 0.170 |
Why?
|
| RNA Splicing | 1 | 2020 | 142 | 0.160 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 395 | 0.160 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 71 | 0.160 |
Why?
|
| Access to Information | 1 | 2018 | 27 | 0.160 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 87 | 0.160 |
Why?
|
| Male | 8 | 2024 | 40988 | 0.160 |
Why?
|
| Mexican Americans | 1 | 2017 | 63 | 0.160 |
Why?
|
| Quantitative Trait Loci | 2 | 2018 | 577 | 0.150 |
Why?
|
| Cohort Studies | 2 | 2022 | 2768 | 0.150 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 329 | 0.150 |
Why?
|
| Models, Genetic | 2 | 2013 | 926 | 0.150 |
Why?
|
| Research | 1 | 2018 | 253 | 0.150 |
Why?
|
| Pharmacogenomic Testing | 1 | 2017 | 97 | 0.140 |
Why?
|
| Brain | 4 | 2002 | 2216 | 0.140 |
Why?
|
| Phylogeny | 1 | 2022 | 1137 | 0.140 |
Why?
|
| Computing Methodologies | 1 | 2016 | 9 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 456 | 0.140 |
Why?
|
| Hemiptera | 2 | 2013 | 7 | 0.140 |
Why?
|
| Pandemics | 1 | 2022 | 740 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2021 | 534 | 0.140 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 265 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 1204 | 0.130 |
Why?
|
| Symbiosis | 2 | 2013 | 118 | 0.130 |
Why?
|
| DNA, Bacterial | 2 | 2013 | 236 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 1075 | 0.130 |
Why?
|
| Students, Medical | 1 | 2020 | 385 | 0.130 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 137 | 0.130 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2011 | 69 | 0.120 |
Why?
|
| Genetic Variation | 2 | 2018 | 1351 | 0.120 |
Why?
|
| Erythroid Cells | 1 | 2013 | 14 | 0.120 |
Why?
|
| Gene Expression | 1 | 2018 | 1284 | 0.120 |
Why?
|
| Systems Integration | 1 | 2014 | 35 | 0.120 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1579 | 0.120 |
Why?
|
| Erythropoiesis | 1 | 2013 | 52 | 0.120 |
Why?
|
| Female | 9 | 2020 | 44550 | 0.120 |
Why?
|
| Binding Sites | 3 | 2014 | 1098 | 0.120 |
Why?
|
| Metagenomics | 1 | 2014 | 83 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2024 | 8496 | 0.110 |
Why?
|
| Incidence | 1 | 2017 | 1578 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2012 | 79 | 0.110 |
Why?
|
| Models, Chemical | 2 | 2004 | 178 | 0.110 |
Why?
|
| Biotechnology | 1 | 2012 | 28 | 0.100 |
Why?
|
| Transcription, Genetic | 2 | 2014 | 1135 | 0.100 |
Why?
|
| Chromosome Deletion | 1 | 2012 | 229 | 0.100 |
Why?
|
| Child | 5 | 2019 | 6928 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1197 | 0.100 |
Why?
|
| Gene Components | 1 | 2011 | 6 | 0.100 |
Why?
|
| Leukemia, Myeloid | 1 | 2012 | 249 | 0.100 |
Why?
|
| Quality Control | 1 | 2011 | 117 | 0.100 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 1384 | 0.100 |
Why?
|
| Forecasting | 1 | 2012 | 305 | 0.100 |
Why?
|
| Conserved Sequence | 1 | 2011 | 210 | 0.090 |
Why?
|
| Research Design | 1 | 2014 | 594 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2017 | 1981 | 0.090 |
Why?
|
| Machine Learning | 2 | 2024 | 232 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2012 | 403 | 0.090 |
Why?
|
| Radiology | 1 | 2012 | 194 | 0.090 |
Why?
|
| Animals | 9 | 2014 | 26590 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 249 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 536 | 0.080 |
Why?
|
| Computer Simulation | 2 | 2018 | 1078 | 0.080 |
Why?
|
| Drosophila Proteins | 2 | 2010 | 488 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 696 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1375 | 0.080 |
Why?
|
| Aged | 3 | 2022 | 18423 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 469 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 2903 | 0.070 |
Why?
|
| Spinal Cord | 2 | 1998 | 249 | 0.070 |
Why?
|
| Spinal Canal | 1 | 1986 | 4 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 2360 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2018 | 7998 | 0.070 |
Why?
|
| Facial Injuries | 1 | 1985 | 19 | 0.070 |
Why?
|
| Pattern Recognition, Automated | 1 | 2006 | 217 | 0.070 |
Why?
|
| Craniocerebral Trauma | 1 | 1985 | 52 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 1208 | 0.060 |
Why?
|
| Genotype | 2 | 2018 | 1852 | 0.060 |
Why?
|
| Xenobiotics | 1 | 2003 | 7 | 0.060 |
Why?
|
| Database Management Systems | 1 | 2003 | 41 | 0.050 |
Why?
|
| Infant, Newborn | 4 | 2019 | 2379 | 0.050 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2014 | 267 | 0.050 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2020 | 5 | 0.050 |
Why?
|
| Histones | 2 | 2013 | 311 | 0.050 |
Why?
|
| College Admission Test | 1 | 2020 | 2 | 0.050 |
Why?
|
| New York City | 1 | 2020 | 59 | 0.050 |
Why?
|
| School Admission Criteria | 1 | 2020 | 23 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 26 | 0.040 |
Why?
|
| Protein Binding | 2 | 2014 | 1457 | 0.040 |
Why?
|
| Infant | 3 | 2019 | 3047 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2019 | 149 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 426 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2019 | 3613 | 0.040 |
Why?
|
| Mass Screening | 1 | 2022 | 619 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 3030 | 0.040 |
Why?
|
| Family Health | 1 | 2017 | 162 | 0.040 |
Why?
|
| Lung | 1 | 2023 | 1169 | 0.040 |
Why?
|
| 3' Untranslated Regions | 1 | 2017 | 92 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 106 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 840 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2018 | 195 | 0.040 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2016 | 6 | 0.040 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2016 | 40 | 0.030 |
Why?
|
| Government Regulation | 1 | 2016 | 49 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 270 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1939 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1188 | 0.030 |
Why?
|
| Confidentiality | 1 | 2016 | 78 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 144 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 677 | 0.030 |
Why?
|
| Pedigree | 1 | 2017 | 966 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2017 | 201 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2018 | 729 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 1056 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 217 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 418 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2019 | 434 | 0.030 |
Why?
|
| Nucleotide Motifs | 1 | 2014 | 47 | 0.030 |
Why?
|
| Hematoma | 2 | 1985 | 104 | 0.030 |
Why?
|
| Health Records, Personal | 1 | 2013 | 11 | 0.030 |
Why?
|
| Penetrance | 1 | 2013 | 44 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2264 | 0.030 |
Why?
|
| Dioxygenases | 1 | 2013 | 74 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 158 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 369 | 0.030 |
Why?
|
| Inpatients | 1 | 1996 | 298 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 12 | 0.030 |
Why?
|
| U937 Cells | 1 | 2012 | 32 | 0.030 |
Why?
|
| K562 Cells | 1 | 2012 | 43 | 0.030 |
Why?
|
| Cytosine | 1 | 2013 | 127 | 0.030 |
Why?
|
| Publishing | 1 | 2014 | 90 | 0.030 |
Why?
|
| Adolescent | 3 | 2019 | 8984 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 187 | 0.030 |
Why?
|
| Adult | 4 | 2019 | 25659 | 0.030 |
Why?
|
| Haploinsufficiency | 1 | 2012 | 62 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2012 | 252 | 0.030 |
Why?
|
| Risk Factors | 1 | 2022 | 5420 | 0.030 |
Why?
|
| Cerebral Hemorrhage | 2 | 1985 | 325 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 265 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2012 | 498 | 0.030 |
Why?
|
| RNA Interference | 1 | 2012 | 369 | 0.030 |
Why?
|
| Silencer Elements, Transcriptional | 1 | 2011 | 5 | 0.030 |
Why?
|
| Insulator Elements | 1 | 2011 | 7 | 0.030 |
Why?
|
| Histone Code | 1 | 2011 | 19 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 458 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 782 | 0.020 |
Why?
|
| RNA, Small Untranslated | 1 | 2010 | 14 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 279 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 826 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2011 | 63 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2010 | 54 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 879 | 0.020 |
Why?
|
| Genes, Insect | 1 | 2010 | 183 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2819 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 1924 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 5980 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 2426 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 481 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 1992 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6513 | 0.020 |
Why?
|
| Spinal Cord Diseases | 1 | 1986 | 29 | 0.020 |
Why?
|
| Birth Injuries | 1 | 1985 | 4 | 0.020 |
Why?
|
| Skull Fractures | 1 | 1985 | 24 | 0.020 |
Why?
|
| Orbital Fractures | 1 | 1985 | 13 | 0.020 |
Why?
|
| Mastoid | 1 | 1985 | 17 | 0.020 |
Why?
|
| Brain Edema | 1 | 1985 | 50 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2357 | 0.020 |
Why?
|
| Brain Concussion | 1 | 1985 | 59 | 0.020 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 1985 | 137 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1985 | 318 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 2 | 1998 | 1037 | 0.010 |
Why?
|
| Middle Aged | 2 | 2017 | 25040 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 11356 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1985 | 2601 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 1998 | 172 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1998 | 268 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 1998 | 220 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1996 | 81 | 0.010 |
Why?
|
| Evoked Potentials | 1 | 1977 | 190 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 1996 | 143 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 1977 | 212 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1996 | 180 | 0.010 |
Why?
|
| Cognition | 1 | 1998 | 571 | 0.010 |
Why?
|
| Contrast Media | 1 | 1998 | 1078 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 1977 | 584 | 0.010 |
Why?
|
| Biomarkers | 1 | 1998 | 1718 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1996 | 763 | 0.010 |
Why?
|
| Haplorhini | 1 | 1977 | 82 | 0.000 |
Why?
|
| Hypotension | 1 | 1977 | 70 | 0.000 |
Why?
|
| Electric Stimulation | 1 | 1977 | 347 | 0.000 |
Why?
|
| Hypertension | 1 | 1977 | 1142 | 0.000 |
Why?
|